Found 147 results for Neoplasm
A listing of Neoplasm medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of Tng462 in Combination with Other Agents in Patients with Pancreatic or Non-Small Cell Lung Cancer with Mtap Loss and Ras Mutation
A
Anita Turk, MD
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with the following agents: RMC-6236, RMC-9805, mFOLFIRINOX, or gemcitabine/nab-paclitaxel. Overall, the study comprises a dose escalation phase and a dose expansion phase.Interested in participating? For …
Randomized Phase Iii Study of Mosunetuzumab Vs. Rituximab for Low Tumor Burden Follicular Lymphoma
K
Khushali Jhaveri
This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of …
Breast Cancer Survivors and Their Partners Needed for Research Study!
R
Rosie Shrout
ARE YOU OR SOMEONE YOU KNOW A BREAST CANCER SURVIVOR?; We need your help!Researchers at Purdue University are exploring how relationships and stress affect couples' immune and cardiovascular systems during breast cancer survivorship.You may be eligible to participate if:You are 18 years or older.You or your partner had breast cancer …
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
N
Naoyuki Saito, MD
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapyults in a non-inferior rate of invasive or non-invasive ipsilateral breast tumorurrence (IBTR) compared to breast conservation with breast radiation and endocrineherapy. Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon …
Specialty Compared to Oncology Delivered Palliative Care for Patients with Acute Myeloid Leukemia SCOPE-Leukemia
L
Larry Cripe, MD
This research study is evaluating whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcomes in patients with acute myeloid leukemia (AML).Interested in participating? For more information about this research study or other cancer-related clinical …
SHORTER ANTHRACYCLINE-FREE CHEMO IMMUNOTHERAPY ADAPTED TOPATHOLOGICAL RESPONSE IN EARLY TRIPLE NEGATIVE BREAST CANCER (SCARLET), ARANDOMIZED PHASE III STUDY
K
Kathy Miller, MD
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in …
Rapid Autopsy Protocol for Patients with Small Cell Lung Cancer
S
Shadia Jalal, MD
This is pilot study to establish a rapid autopsy program in Small Cell Lung Cancer (SCLC) at the Indiana University Simon Comprehensive Cancer Center and outline the components necessary for tumor tissue collection. This proposal is a collaboration between scientists, lung cancer physicians, pathologists, and the IUSCCC Translational Research Core. …
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
T
Tareq Salous
What is this study about?This phase II/III trial examines whether patients who have undergone surgical removal of bladder, but require an additional treatment called immunotherapy to help prevent their bladder cancer from coming back, can be identified by a blood test. Many types of tumors tend to lose cells or …
Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab
N
Nasser Hanna, MD
This research aims to incorporate ctDNA analysis into clinical practice to individualize therapy in patients with stage III NSCLC by moving to a treatment-by-marker based approach (as opposed to treatment based on clinical or radiographic evidence of disease). Interested in participating? For more information about this research study or other cancer-related …
Phase I/II Trial of Lurbinectedin with Osimertinib in Transformed Small Cell Lung Cancer
M
Misty D. Shields, MD, PhD
Primary Objective:To assess the efficacy of the combination of lurbinectedin with osimertinib in patients with EGFR altered non-small cell lung cancer (NSCLC) with documented transformation to SCLC, after the use of EGFR tyrosine kinase inhibitor osimertinib.Secondary ObjectiveTo evaluate the safety of the combination of lurbinectedin with osimertinib in patients with …
Please choose between Voice or SMS based delivery of verification code
or